← Human Trials & Peer-Reviewed Studies
The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study
Plain-language guide to PMID 28474780 (2017): double-blind randomized controlled trial study of Abaloparatide in 821 women.
Key Facts
- PMID
- 28474780
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- McCloskey EV et al. (8 authors)
- DOI
- 10.1002/jbmr.3163
What This Study Did, in Plain Language
What Was Tested
Researchers studied Abaloparatide in this randomized controlled trial publication.
Baseline clinical risk factors (age, body mass index [BMI], prior fracture, glucocorticoid use, rheumatoid arthritis, and smoking) were entered into country-specific FRAX models to calculate the 10-year probability of major osteoporotic fractures, with or without femoral neck bone mineral density (BMD).
Who Took Part
The abstract describes 821 women taking part.
PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.
A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The women were allocated by chance, so the Abaloparatide group and the comparison group should start out alike.
Blinding on both sides kept the women and researchers unaware of who received Abaloparatide.
The comparison arm used a placebo, so changes seen with Abaloparatide could be set against what happens without it.
A time span of 2 years appears in the methods.
What Was Measured
The subject headings attached to it are Age Factors, Body Mass Index, Bone Density, Femoral Neck Fractures, Femur Neck, Osteoporosis, Postmenopausal and Parathyroid Hormone-Related Protein.
The authors tagged it with the keywords ABALOPARATIDE-SC, FRACTURE RISK and FRAX.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Abaloparatide in 821 women over 2 years.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2017 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Abaloparatide compound page, all human trials.
Our Notes on the Compound
Abaloparatide: A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.